Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner:
Adrienne Matson, PharmD, BCPS–has no relevant financial relationships to disclose in relation to the content of this activity.

Content Development Faculty:
Mikhail Kosiborod, MD, FACC, FAHA–has disclosed that he is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, Eisai, Glytec, GlaxoSmithKline, Merck, Novo Nordisk, Sanofi Aventis, and ZS Pharma; receives grant/research support from AstraZeneca and Boehringer Ingelheim.
Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA–has disclosed that he is a consultant for AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Servier, and Sanofi Aventis; receives grant/research support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Merck, Novo Nordisk and Sanofi Aventis. He is also a member of the speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Servier, and Sanofi Aventis.
Kim Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE, CLS–has no relevant financial relationships to disclose in relation to the content of this activity.
Melissa Magwire, RN, CDE–has no relevant financial relationships to disclose in relation to the content of this activity.

Speaking Faculty:
Jarett D. Berry, MD–has disclosed that he is a member of the speakers’ bureau for Merck.
Mark Stolar, MD–has disclosed that he is a member of the speakers' bureau for AstraZeneca.
Darren K. McGuire, MD, MHSc–has disclosed that he is a consultant for AstraZeneca, Boehringer Ingelheim, Lilly, Merck & Co, Pfizer, Novo Nordisk, and Sanofi Aventis. He receives grant/research support from AstraZeneca, Boehringer Ingelheim, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Merck & Co, Novo Nordisk, and Sanofi Aventis.
Jonathan D. Newman, MD, MPH, FAHA, FACC–has no relevant financial relationships to disclose in relation to the content of this activity.
Tracy Y. Wang, MD, MHS, MSc–has disclosed that she is a consultant for Gilead, Merck, and Sanofi and receives grant/research to her institute, Duke Clinical Research Institute, from AstraZeneca, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Lilly, Gilead Sciences, Novartis, Pfizer, and Regeneron, Dr. Wang herself has received grant/research support from AstraZeneca, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, Lilly, Novartis, Pfizer, and Regeneron.

Peer Reviewers:
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Tom Maddox, MD – has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Scott Urquhart, PA-C, DFAAPA–has disclosed that he is a consultant for Novo Nordisk; an advisory board member for AstraZeneca and Sanofi; and a member of the speakers' bureau for AstraZeneca and Novo Nordisk.